Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Merck & (MRK)

Merck Reports Q3 2026 Sales of $18.1 Billion and Raises Full-Year Guidance

Mixed Impact 4 of 5 guidance

Merck reported worldwide sales of $18.1 billion for the third quarter of 2026, representing a 5% increase compared to the same period in 2025. GAAP EPS was $2.04 and non-GAAP EPS was $2.49, both impacted by a one-time charge related to a global license agreement with SciBrunch. The company also narrowed and raised its full-year 2026 financial outlook for sales and non-GAAP EPS.

Key points

  • Total worldwide sales reached $18.1 billion in Q3 2026, up 5% from $17.276 billion in Q3 2025.
  • KEYTRUDA sales grew 6% to $8.6 billion, and WINREVAIR sales surged 93% to $694 million.
  • Full-year 2026 sales outlook was raised to a range of $66.8 billion to $67.3 billion.
  • Full-year 2026 non-GAAP EPS outlook was raised to a range of $2.77 to $2.82.

The filing

CompanyMerck & (MRK)
Form8-K, current report
Filed with the SECOct 29, 2026, 6:43 AM ET
Accession number0001104659-26-119825

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Oct 29, 2026, 7:17 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.